F. Carrera

Learn More
TABLES Table 1. Prevalence of HCV infection in hemodialysis patients from various countries S8 Table 2. Summary Table of baseline characteristics of hemodialysis patients tested for HCV (EIA vs. NAT) S16 Table 3. Summary Table of testing for HCV in hemodialysis patients (EIA vs. NAT) S17 Table 4. Evidence Profile for diagnostic testing for HCV in(More)
BACKGROUND Several studies with erythropoiesis-stimulating agents claim that maintenance therapy of renal anaemia may be possible at extended dosing intervals; however, few studies were randomized, results varied, and comparisons between agents were absent. We report results of a multi-national, randomized, prospective trial comparing haemoglobin(More)
BACKGROUND The optimal iron therapy regimen in patients with non-dialysis-dependent chronic kidney disease (CKD) is unknown. METHODS Ferinject® assessment in patients with Iron deficiency anaemia and Non-Dialysis-dependent Chronic Kidney Disease (FIND-CKD) was a 56-week, open-label, multicentre, prospective and randomized study of 626 patients with(More)
BACKGROUND Rigorous data are sparse concerning the optimal route of administration and dosing strategy for iron therapy with or without concomitant erythropoiesis-stimulating agent (ESA) therapy for the management of iron deficiency anaemia in patients with non-dialysis dependent chronic kidney disease (ND-CKD). METHODS FIND-CKD was a 56-week, open-label,(More)
The forest certification process in Guatemala has largely been confined to the forest concessions in the Maya Biosphere Reserve (MBR), representing 95% of the country's certified forest area. Forest certification in Guatemala is unique in that certification in accordance with the scheme of the Forest Stewardship Council (FSC) is mandatory for both(More)
Background. Erythropoiesis-stimulating agents (ESAs) such as epoetin alfa and beta, and darbepoetin alfa have improved the management of anaemia secondary to chronic kidney disease. Numerous studies have reported a dose reduction when patients receiving dialysis were converted from epoetin to darbepoetin alfa using the starting dose conversion of 200:1 as(More)
The development of secondary hyperparathyroidism (SHPT) is a common complication of chronic kidney disease. SHPT develops as a consequence of mineral metabolism disturbances and is characterized by elevated serum parathyroid hormone (PTH) and parathyroid hyperplasia. Evidence suggests that SHPT contributes to the development of vascular calcification and(More)
The introduction of erythropoiesis-stimulating agents (ESAs) into everyday clinical practice has greatly improved the care of patients with chronic kidney disease. ESAs have reduced the need for blood transfusions, improved survival, decreased cardiovascular complications and enhanced patient quality of life. The longer acting ESA, darbepoetin alfa (Aranesp(More)